These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18051740)

  • 1. Cerebrotendinous xanthomatosis: a treatable cause of metabolic ataxia.
    Mukherjee AA; Chawla BP; Rathi SS; Puthran RS
    J Assoc Physicians India; 2007 Sep; 55():655-7. PubMed ID: 18051740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cerebrotendinous xanthomatosis].
    Burghaus L; Liu W; Haupt WF
    Dtsch Med Wochenschr; 2007 Jul; 132(27):1463-6. PubMed ID: 17583829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrotendinous xanthomatosis in three siblings from a Chinese family.
    Ko KF; Lee KW
    Singapore Med J; 2001 Jan; 42(1):30-2. PubMed ID: 11361235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study.
    Isenhardt K; Schmitt R; Nagel A; Drach L; Schlote W
    Clin Neuropathol; 2005; 24(6):276-83. PubMed ID: 16320823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrotendinous xanthomatosis: a treatable ataxia.
    Clemen CS; Spottke EA; Lütjohann D; Urbach H; von Bergmann K; Klockgether T; Dodel R
    Neurology; 2005 Apr; 64(8):1476. PubMed ID: 15851751
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebrotendinous xanthomatosis: clinical and imaging clues of a rare treatable cause of ataxia.
    Magriço M; Cabral P; Bugalho P
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35858741
    [No Abstract]   [Full Text] [Related]  

  • 7. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
    Weissfeld T; Ratliff J
    J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrotendinous xanthomatosis: a rare cause of spinocerebellar syndrome.
    Ostrowska M; Banaszkiewicz K; Kiławiec A; Róg T; Lütjohann D; Szczudlik A
    Neurol Neurochir Pol; 2011; 45(6):600-603. PubMed ID: 22212991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Treatable Rare Cause of Progressive Ataxia and Palatal Tremor.
    Rossi M; Cesarini M; Gatto EM; Cammarota A; Merello M
    Tremor Other Hyperkinet Mov (N Y); 2018; 8():538. PubMed ID: 29971195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.
    Berginer VM; Gross B; Morad K; Kfir N; Morkos S; Aaref S; Falik-Zaccai TC
    Pediatrics; 2009 Jan; 123(1):143-7. PubMed ID: 19117873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report.
    Luyckx E; Eyskens F; Simons A; Beckx K; Van West D; Dhar M
    Clin Neurol Neurosurg; 2014 Mar; 118():9-11. PubMed ID: 24529221
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cerebrotendinous xanthomatosis is a rare disorder, which requires a specific treatment].
    Blaabjerg M; Marjanovic D
    Ugeskr Laeger; 2013 Jan; 175(5):285-6. PubMed ID: 23369332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
    Dotti MT; Lütjohann D; von Bergmann K; Federico A
    Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
    Heller R; Grau AJ; Schäbitz WR; Schwaninger M
    Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary heart disease in a patient with cerebrotendinous xanthomatosis.
    Valdivielso P; Calandra S; Durán JC; Garuti R; Herrera E; González P
    J Intern Med; 2004 Jun; 255(6):680-3. PubMed ID: 15147532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The wide spectrum of cerebrotendinous xanthomatosis: Case report of a rare but treatable disease.
    Rosafio F; Cavallieri F; Guaraldi P; Taroni F; Nichelli PF; Mandrioli J
    Clin Neurol Neurosurg; 2016 Apr; 143():1-3. PubMed ID: 26874936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrotendinous xanthomatosis: a treatable neurodegenerative disease.
    Sandeep P; Jayakrishnan C; Sadanan S; Sreekumar S; Thulasidharan NK
    J Assoc Physicians India; 2009 Oct; 57():716-7. PubMed ID: 20329433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
    Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
    Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cerebrotendinous xanthomatosis, a rare, severe, but treatable metabolic disorder].
    Delstanche S; Deflandre T; Otto B; Tshibanda L; Simoni P; Moonen G
    Rev Med Liege; 2013 Apr; 68(4):171-6. PubMed ID: 23755706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
    Huidekoper HH; Vaz FM; Verrips A; Bosch AM
    Eur J Pediatr; 2016 Jan; 175(1):143-6. PubMed ID: 26156051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.